356 related articles for article (PubMed ID: 3037302)
1. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
2. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Eng WK; McCabe FL; Tan KB; Mattern MR; Hofmann GA; Woessner RD; Hertzberg RP; Johnson RK
Mol Pharmacol; 1990 Oct; 38(4):471-80. PubMed ID: 2172765
[TBL] [Abstract][Full Text] [Related]
3. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
5. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines.
Deffie AM; Batra JK; Goldenberg GJ
Cancer Res; 1989 Jan; 49(1):58-62. PubMed ID: 2535693
[TBL] [Abstract][Full Text] [Related]
6. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
[TBL] [Abstract][Full Text] [Related]
7. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
8. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
9. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Utsugi T; Mattern MR; Mirabelli CK; Hanna N
Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.
Finlay GJ; Holdaway KM; Baguley BC
Oncol Res; 1994; 6(1):33-7. PubMed ID: 7919550
[TBL] [Abstract][Full Text] [Related]
12. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
13. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
14. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells.
Deffie AM; Bosman DJ; Goldenberg GJ
Cancer Res; 1989 Dec; 49(24 Pt 1):6879-82. PubMed ID: 2555055
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
[TBL] [Abstract][Full Text] [Related]
17. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK
Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
[TBL] [Abstract][Full Text] [Related]
19. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors.
Pommier Y; Schwartz RE; Zwelling LA; Kerrigan D; Mattern MR; Charcosset JY; Jacquemin-Sablon A; Kohn KW
Cancer Res; 1986 Feb; 46(2):611-6. PubMed ID: 3000581
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
